Literature DB >> 17687007

Evolution of an international external quality assurance model to support laboratory investigation of Streptococcus pneumoniae, developed for the SIREVA project in Latin America, from 1993 to 2005.

Marguerite Lovgren1, James A Talbot, Maria Cristina Brandileone, Silvana T Casagrande, Clara Inés Agudelo, Elizabeth Castañeda, Mabel Regueira, Alejandra Corso, Ingrid Heitmann, Aurora Maldonado, Gabriela Echániz-Avilés, Araceli Soto-Noguerón, María Hortal, Teresa Camou, Jean-Marc Gabastou, José Luis Di Fabio.   

Abstract

In 1993 the Pan American Health Organization initiated a laboratory-based surveillance system, called the SIREVA project, to learn about Streptococcus pneumoniae invasive disease in Latin American children. In 1994, National Laboratories in six countries were trained to perform serotyping and antibiotic susceptibility testing using broth microdilution to determine the MIC for specified antibiotics. An international External Quality Assurance (EQA) program was developed to monitor and support ongoing laboratory performance. The EQA program was coordinated by the National Centre for Streptococcus (NCS), Edmonton, Canada, and included external proficiency testing (EPT) and a validation process requiring regular submission of a sample of isolates from each laboratory to the NCS for verification of the serotype and MIC. In 1999, the EQA program was decentralized to use three of the original laboratories as regional quality control centers to address operational concerns and to accommodate the growth of the laboratory network to more than 20 countries including the Caribbean region. The overall EPT serotyping accuracies for phase I (1993 to 1998) and phase II (1999 to 2005) were 88.0 and 93.8%, respectively; the MIC correlations within +/-1 log(2) dilution of the expected result were 83.0 and 91.0% and the interpretive category agreements were 89.1 and 95.3%. Overall, the validation process serotyping accuracies for phases I and II were 81.9 and 88.1%, respectively, 80.4 and 90.5% for MIC agreement, and 85.8 and 94.3% for category agreement. These results indicate a high level of testing accuracy in participating National Laboratories and a sustained increase in EQA participation in Latin America and the Caribbean.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17687007      PMCID: PMC2045357          DOI: 10.1128/JCM.00789-07

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  External quality assessment of antimicrobial susceptibility testing in Europe.

Authors:  J J Snell; D F Brown
Journal:  J Antimicrob Chemother       Date:  2001-06       Impact factor: 5.790

2.  Assessment of laboratory performance with Streptococcus pneumoniae antimicrobial susceptibility testing in the United States: a report from the College of American Pathologists Microbiology Proficiency Survey Program.

Authors:  G V Doern; A B Brueggemann; M A Pfaller; R N Jones
Journal:  Arch Pathol Lab Med       Date:  1999-04       Impact factor: 5.534

3.  The World Health Organization's External Quality Assurance System Proficiency Testing Program has improved the accuracy of antimicrobial susceptibility testing and reporting among participating laboratories using NCCLS methods.

Authors:  Jasmine M Chaitram; Laura A Jevitt; Sara Lary; Fred C Tenover
Journal:  J Clin Microbiol       Date:  2003-06       Impact factor: 5.948

4.  Evolution of Streptococcus pneumoniae serotypes and penicillin susceptibility in Latin America, Sireva-Vigía Group, 1993 to 1999. PAHO Sireva-Vigía Study Group. Pan American Health Organization.

Authors:  J L Di Fabio; E Castañeda; C I Agudelo; F De La Hoz; M Hortal; T Camou; G Echániz-Avilés; M Noemi; C Barajas; I Heitmann; J C Hormazabal; M C Brandileone; V S Dias Vieira; M Regueira; R Ruvinski; A Corso; M Lovgren; J A Talbot; C De Quadros
Journal:  Pediatr Infect Dis J       Date:  2001-10       Impact factor: 2.129

Review 5.  Pan American Health Organization epidemiological surveillance network for Streptococcus pneumoniae.

Authors:  J L di Fabio; A Homma; C de Quadros
Journal:  Microb Drug Resist       Date:  1997       Impact factor: 3.431

6.  Typing of pneumococci by using 12 pooled antisera.

Authors:  U B Sørensen
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

7.  Validation of serotyping of Streptococcus pneumoniae in Europe.

Authors:  Helle Bossen Konradsen
Journal:  Vaccine       Date:  2005-02-03       Impact factor: 3.641

8.  Ability of laboratories to detect emerging antimicrobial resistance: proficiency testing and quality control results from the World Health Organization's external quality assurance system for antimicrobial susceptibility testing.

Authors:  F C Tenover; M J Mohammed; J Stelling; T O'Brien; R Williams
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

9.  Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization Surveillance Study.

Authors:  D A Kertesz; J L Di Fabio; M C de Cunto Brandileone; E Castañeda; G Echániz-Aviles; I Heitmann; A Homma; M Hortal; M Lovgren; R O Ruvinsky; J A Talbot; J Weekes; J S Spika
Journal:  Clin Infect Dis       Date:  1998-06       Impact factor: 9.079

  9 in total
  9 in total

1.  The International Circumpolar Surveillance interlaboratory quality control program for Streptococcus pneumoniae, 1999 to 2008.

Authors:  A Reasonover; T Zulz; M G Bruce; D Bruden; L Jetté; M Kaltoft; L Lambertsen; A Parkinson; K Rudolph; M Lovgren
Journal:  J Clin Microbiol       Date:  2010-11-03       Impact factor: 5.948

2.  [Regional System for Vaccines (SIREVA), laboratory surveillance and vaccine development for Streptococcus pneumoniae: bibliometric analysis, 1993-2019].

Authors:  José Luis Di Fabio; Clara Inés Agudelo; Elizabeth Castañeda
Journal:  Rev Panam Salud Publica       Date:  2020-08-06

3.  [Evolution of the performance of Latin America Reference Laboratories in the detection of mechanisms of antimicrobial resistanceEvolução do desempenho dos Laboratórios de Referência na América Latina na detecção de mecanismos de resistência antimicrobiana].

Authors:  Paula Gagetti; Fernando Pasteran; Paola Ceriana; Mónica Prieto; Lucía Cipolla; Ezequiel Tuduri; Nienke Bruinsma; Marcelo Galas; Pilar Ramón-Pardo; A Corso
Journal:  Rev Panam Salud Publica       Date:  2020-09-23

Review 4.  Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010.

Authors:  Elizabeth Castañeda; Clara Inés Agudelo; Rodrigo De Antonio; Diego Rosselli; Claudia Calderón; Eduardo Ortega-Barria; Rómulo E Colindres
Journal:  BMC Infect Dis       Date:  2012-05-28       Impact factor: 3.090

5.  Capsular serotyping of Streptococcus pneumoniae using the Quellung reaction.

Authors:  Maha Habib; Barbara D Porter; Catherine Satzke
Journal:  J Vis Exp       Date:  2014-02-24       Impact factor: 1.355

6.  Effect of pneumococcal conjugate vaccination in Uruguay, a middle-income country.

Authors:  Gabriela García Gabarrot; Mariana López Vega; Gabriel Pérez Giffoni; Silvia Hernández; Pablo Cardinal; Viviana Félix; Jean Marc Gabastou; Teresa Camou
Journal:  PLoS One       Date:  2014-11-06       Impact factor: 3.240

7.  External Quality Assurance for Laboratory Identification and Capsular Typing of Streptococcus pneumoniae.

Authors:  Hans-Christian Slotved; Carmen L Sheppard; Tine Dalby; Arie van der Ende; Norman K Fry; Eva Morfeldt; Outi Nyholm; Assaf Rokney; Merav Ron; Lotta Siira; Kevin J Scott; Andrew Smith; Louise Thom; Maija Toropainen; Didrik F Vestrheim
Journal:  Sci Rep       Date:  2017-10-16       Impact factor: 4.379

8.  Laboratory-based surveillance of Neisseria meningitidis isolates from disease cases in Latin American and Caribbean countries, SIREVA II 2006-2010.

Authors:  Ana Belén Ibarz-Pavón; Ana Paula Lemos; Maria Cecilia Gorla; Mabel Regueira; Jean-Marc Gabastou
Journal:  PLoS One       Date:  2012-08-30       Impact factor: 3.240

9.  Clinical and bacteriological characteristics of invasive pneumococcal disease after pneumococcal 10-valent conjugate vaccine implementation in Salvador, Brazil.

Authors:  Carolina Regis Leite; Jailton Azevedo; Vivian Santos Galvão; Otávio Moreno-Carvalho; Joice Neves Reis; Cristiana Nascimento-Carvalho
Journal:  Braz J Infect Dis       Date:  2015-12-17       Impact factor: 3.257

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.